These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 17408047

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [What's new about hyperactivity disorder in children?].
    Le Heuzey MF.
    Arch Pediatr; 2008 Jul; 15(7):1249-52. PubMed ID: 18485682
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Attention deficit hyperactivity disorders in children and adolescents: diagnostic and therapeutic guidelines].
    Lehmkuhl G.
    MMW Fortschr Med; 2007 May 21; 149 Suppl 2():10-3; quiz 14. PubMed ID: 17724960
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
    Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ.
    J Child Adolesc Psychopharmacol; 2013 Apr 21; 23(3):179-93. PubMed ID: 23560600
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.
    Slatkoff J, Greenfield B.
    Expert Opin Investig Drugs; 2006 Jun 21; 15(6):649-67. PubMed ID: 16732717
    [Abstract] [Full Text] [Related]

  • 10. Attention deficit hyperactivity disorder: part III.
    Ryan-Krause P.
    J Pediatr Health Care; 2011 Jun 21; 25(1):50-6. PubMed ID: 21147408
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 21; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 13. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, Montoya A, Quail D, Escobar R.
    J Clin Psychopharmacol; 2013 Dec 21; 33(6):766-74. PubMed ID: 23963057
    [Abstract] [Full Text] [Related]

  • 14. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr 21; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M, Dahl AA, Martinsen EW, Klungsøyr O, Haavik J, Peleikis DE.
    Eur Neuropsychopharmacol; 2014 Dec 21; 24(12):1873-84. PubMed ID: 25453480
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Improving decision making in the treatment of ADHD.
    Vitiello B.
    Am J Psychiatry; 2008 Jun 21; 165(6):666-7. PubMed ID: 18519529
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.